RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Trachoma is caused by Chlamydia trachomatis and is the leading infectious cause of preventable blindness globally. For trachoma control, the World Health Organization (WHO) promotes the SAFE strategy, an integrated program of 1) eyelid Surgery to correct the in-turned eyelashes associated with severe trachoma and stops pain and minimizes risk of corneal damage; 2) Antibiotic treatment for active trachoma using single-dose oral azithromycin or tetracycline eye ointment; 3) Facial cleanliness through sustained behavior change to reduce transmission; and 4) Environmental improvement, to increase access to water and sanitation [1],[2]. The A, F, and E components of SAFE have been designed to treat ocular Chlamydia infection and reduce the risk of trachoma transmission, such that blinding trachoma is eliminated.